Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Decreases By 30.0%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 3,500 shares, a decline of 30.0% from the October 31st total of 5,000 shares. Based on an average daily volume of 5,600 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. TFC Financial Management Inc. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $87,000.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded down $0.63 during midday trading on Friday, hitting $9.06. The company’s stock had a trading volume of 1,116 shares, compared to its average volume of 10,056. NewAmsterdam Pharma has a 1-year low of $1.81 and a 1-year high of $16.75. The company has a 50-day moving average price of $9.33 and a two-hundred day moving average price of $8.59.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.